DICE THERAPEUTICS PARTNER WITH CRO-SOLUTIONS “It’s been an absolute pleasure working with the CROS team. We are VERY fortunate to be working with a strong Project Management team from CROS
ARXX THERAPEUTICS PARTNER WITH CRO SOLUTIONS CRO Solutions and it’s sisters company, the Medicines Evaluation Unit, have recently partnered with Arxx Therapeutics. We happy to share that, with the help
Two-part Phase 1b trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of inhaled pan-JAK inhibitor KN-002 Study is being conducted at the Medicines Evaluation Unit in Manchester, UK
FIRST PATIENT DOSED IN PHASE 2 STUDY FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY CAUSED BY COVID-19 The initiation of the Phase 2 study in patients in
